On June 4, Argenx SE rose 4.08% in regular trading, trading at $846.29/share, with trading volume of approximately $109 million.

The rise comes amid sustained bullish sentiment surrounding Argenx's core product Vyvgart. RBC Capital Markets recently noted that the company appears confident of a Q2 rebound, citing robust Vyvgart momentum driven by high demand and record new patient starts in Q1. Analysts highlighted that Vyvgart does not require serotype confirmation before use, potentially eliminating a rate-limiting step in prescribing, though formulary access could take up to six months. Additionally, RBC identified the upcoming myositis data readout on track for Q3 as the biggest potential catalyst for the stock.

Vyvgart sales have demonstrated exceptional market penetration, growing from $329 million in 2022 to $2.186 billion in 2024. Bernstein has projected Vyvgart could become the fourth-largest autoimmune drug in history. On May 7, Argenx reported Q1 EPS of $5.52, reinforcing its position as one of the fastest biotech companies to reach profitability.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)